Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy

© 2018 British Society for Haematology and John Wiley & Sons Ltd Some patients with relapsed/refractory Hodgkin lymphoma (HL) are not considered suitable for stem cell transplant (SCT) and have a poor prognosis. This phase IV study (NCT01990534) evaluated brentuximab vedotin (1·8 mg/kg intrave...

Full description

Saved in:
Bibliographic Details
Main Authors: Jan Walewski, Andrzej Hellmann, Noppadol Siritanaratkul, Guner Hayri Ozsan, Muhit Ozcan, Suporn Chuncharunee, Ai Sim Goh, Wojciech Jurczak, Jan Koren, Ewa Paszkiewicz-Kozik, Bingxia Wang, Shalini Singh, Dirk Huebner, Andreas Engert, Bastian von Tresckow
Other Authors: Hospital Pulau Pinang
Format: Article
Published: 2019
Subjects:
Medicine
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/46230
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University

Internet

https://repository.li.mahidol.ac.th/handle/123456789/46230

Similar Items